Abstract

Recent studies have shown that microRNAs (miRNAs) play a role as regulators of neurodevelopment by modulating gene expression. Altered miRNA expression has been reported in various psychiatric disorders, including schizophrenia. However, the changes in the miRNA expression profile that occur during the initial stage of schizophrenia have not been fully investigated. To explore the global alterations in miRNA expression profiles that may be associated with the onset of schizophrenia, we first profiled miRNA expression in plasma from 17 patients with first-episode schizophrenia and 17 healthy controls using microarray analysis. Among the miRNAs that showed robust changes, the elevated expression of has-miR-223-3p (miR-223) was validated via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using another independent sample set of 21 schizophrenia patients and 21 controls. To identify the putative targets of miR-223, we conducted a genome-wide gene expression analysis in neuronally differentiated SK-N-SH cells with stable miR-223 overexpression and an in silico analysis. We found that the mRNA expression levels of four genes related to the cytoskeleton or cell migration were significantly downregulated in miR-223-overexpressing cells, possibly due to interactions with miR-223. The in silico analysis suggested the presence of miR-223 target sites in these four genes. Lastly, a luciferase assay confirmed that miR-223 directly interacted with the 3′ untranslated regions (UTRs) of all four genes. Our results reveal an increase in miR-223 in plasma during both the first episode and the later stage of schizophrenia, which may affect the expression of cell migration-related genes targeted by miR-223.

Details

Title
Altered expression of microRNA-223 in the plasma of patients with first-episode schizophrenia and its possible relation to neuronal migration-related genes
Author
Zhao, Zhilei 1 ; Jinde, Seiichiro 2 ; Koike, Shinsuke 2   VIAFID ORCID Logo  ; Tada, Mariko 2 ; Satomura, Yoshihiro 2 ; Yoshikawa, Akane 2 ; Nishimura, Yukika 2 ; Takizawa, Ryu 2 ; Kinoshita, Akihide 2 ; Sakakibara, Eisuke 2 ; Sakurada, Hanako 2 ; Yamagishi, Mika 2 ; Nishimura, Fumichika 2 ; Inai, Aya 3 ; Nishioka, Masaki 2 ; Eriguchi, Yosuke 3 ; Araki, Tsuyoshi 2 ; Takaya, Atsuhiko 4 ; Kan, Chiemi 5 ; Umeda, Maki 6 ; Shimazu, Akihito 7 ; Hashimoto, Hideki 8 ; Bundo, Miki 9 ; Iwamoto, Kazuya 9   VIAFID ORCID Logo  ; Kakiuchi, Chihiro 2 ; Kasai, Kiyoto 1 

 Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; International Research Center for Neurointelligence, The University of Tokyo, Tokyo, Japan 
 Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan 
 Department of Child Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan 
 Department of Psychiatry, Fukui Kinen Hospital, Miura City, Kanagawa, Japan 
 Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan 
 Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; Department of Public Health Nursing, Graduate School of Nursing Science, St. Luke’s International University, Tokyo, Japan 
 Center for Human and Social Sciences, College of Liberal Arts and Sciences, Kitasato University, Sagamihara City, Kanagawa, Japan 
 Department of Health Economics and Epidemiology Research, School of Public Health, the University of Tokyo, Tokyo, Japan 
 Department of Molecular Brain Science, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan 
Pages
1-11
Publication year
2019
Publication date
Nov 2019
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2313638645
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.